Eplontersen pregnancy and breastfeeding safety study
Part of Brain & nervous system, Cancer, Heart & circulation clinical trials.
This study tracks the safety of eplontersen during pregnancy and breastfeeding by collecting reports from people who have taken it. It helps doctors understand any risks to the baby or mother.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child took eplontersen during pregnancy or while breastfeeding
- You or your child has a condition that eplontersen is approved to treat
- If you had a baby, any health problems in the first year of life that might be linked to eplontersen are reported
- You are willing to provide information and be contacted for follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who already took part in an earlier trial (D8450R00003) to see how safe eplontersen is over the long term. It also includes people who had a liver transplant or severe liver problems.
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
This study follows pregnant people who either took TEGSEDI or did not take it, to better understand pregnancy outcomes in transthyretin amyloid polyneuropathy (hATTR-PN). Your participation may help doctors guide safer pregnancy care for people with this condition.
This program tracks pregnancy outcomes for people who were exposed to patisiran (a medicine) in a special delivery form called LNP during pregnancy or shortly before. It helps doctors understand potential effects and safety for mothers and babies.
This trial checks the long-term safety and side effects of an oral medicine called dersimelagon in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). It is mainly for people who have already finished an earlier dersimelagon study and are able to keep coming to clinic visits.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
Hear when a new Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.